1st Quarter - Report

TCH GROUP, LLC for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IBAP); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR2245 "Preserving Access to Life-Saving Medications Act of 2011" - all provisions; HR 3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenze pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of Dengue; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."

Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3627 (112th), H.R. 2529 (112th), H.R. 2245 (112th)

Medicare/Medicaid MMM

Issues related to changing reimbursement for physicians under the Medicare Part B program

Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

General discussion regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA)

Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.